Mingxia Chen1, Xiaoqing Yang2, Min Yang2, Wei Zhang3, Lei Li3, Qing Sun4. 1. Department of Pathology, Qian-FO-Shan Hospital Affiliated Shandong University, 16766 Jingshi Road, Jinan 250014, China; Department of Pathology, Yatai Yaitaishan Hospital, 91 Jiefang Road, Yatai 264001, China. 2. Department of Pathology, Qian-FO-Shan Hospital Affiliated Shandong University, 16766 Jingshi Road, Jinan 250014, China. 3. Department of Pathology, Yatai Yaitaishan Hospital, 91 Jiefang Road, Yatai 264001, China. 4. Department of Pathology, Qian-FO-Shan Hospital Affiliated Shandong University, 16766 Jingshi Road, Jinan 250014, China. Electronic address: yt-wh@163.com.
Abstract
PURPOSE: To screen novel candidate biomarkers in primary colorectal cancer (CRC), and indentify their clinical valuation in progress of colorectal cancer. METHODS: By using antibody microarray, 274 target proteins in tissue samples from primary colorectal cancer patients were detected. Among differently expressed proteins in CRC tissues, As promising candidate biomarker, RANTES/CCL5 was validated by enzyme-linked immunosorbentassay and immunohistochemistry (IHC), and the clinical significance of CCL5 was analyzed. RESULTS: Totally, 25 differentially expressed proteins were indentified between colorectal cancers and matched normal mucosa. CCL5 expression was significantly associated with adverse pathological progress, apt to lymph node metastasis and higher T stage. CONCLUSIONS: CCL5 may contribute to promoting tumor growth, and CCL5 is a promising target that may help in understanding the pathogenesis of CRC.
PURPOSE: To screen novel candidate biomarkers in primary colorectal cancer (CRC), and indentify their clinical valuation in progress of colorectal cancer. METHODS: By using antibody microarray, 274 target proteins in tissue samples from primary colorectal cancerpatients were detected. Among differently expressed proteins in CRC tissues, As promising candidate biomarker, RANTES/CCL5 was validated by enzyme-linked immunosorbentassay and immunohistochemistry (IHC), and the clinical significance of CCL5 was analyzed. RESULTS: Totally, 25 differentially expressed proteins were indentified between colorectal cancers and matched normal mucosa. CCL5 expression was significantly associated with adverse pathological progress, apt to lymph node metastasis and higher T stage. CONCLUSIONS:CCL5 may contribute to promoting tumor growth, and CCL5 is a promising target that may help in understanding the pathogenesis of CRC.
Authors: Asim Pervaiz; Michael Zepp; Rania Georges; Frank Bergmann; Saqib Mahmood; Syeda Faiza; Martin R Berger; Hassan Adwan Journal: J Cancer Res Clin Oncol Date: 2020-09-09 Impact factor: 4.553